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Organophosphates are undergoing increasing
restrictions on their home use in the United
States (U.S. Environmental Protection
Agency 2000, 2002), but nonetheless they
still account for > 50% of all insecticide use
(Casida and Quistad 2004). One of the major
concerns for human health is the propensity
of these agents to produce developmental
neurotoxicity, even when exposures are too
low to elicit signs of systemic intoxication
(Landrigan 2001; Landrigan et al. 1999; May
2000; Physicians for Social Responsibility
1995; Pope 1999; Slotkin 1999, 2004; Weiss
et al. 2004). In that regard, chlorpyrifos has
been the most studied organophosphate, and
it is now clear that the original view of its
mechanism of action—cholinesterase inhibi-
tion via its active metabolite, chlorpyrifos
oxon—is insufﬁcient to explain its ability to
damage the developing brain. In fact, multi-
ple mechanisms target neural cell replication
and differentiation, axonogenesis and synap-
togenesis, and the development and program-
ming of synaptic activity, culminating in
behavioral deﬁcits (Barone et al. 2000; Casida
and Quistad 2004; Gupta 2004; Pope 1999;
Qiao et al. 2002, 2003; Yanai et al. 2002).
There is an important corollary of the com-
pound mechanisms for disruption of brain
development: Whereas all organophosphates
share actions directed toward cholinesterase,
they may differ substantially in many of their
noncholinesterase effects, such as actions
directed toward oxidative stress, cell signaling,
expression and function of nuclear transcrip-
tion factors, and cell replication and differen-
tiation (Gupta 2004; Pope 1999; Slotkin
1999, 2004, 2005), even if some of those
additional mechanisms are shared by various
organophosphates (Abu-Qare and Abou-
Donia 2001; Morale et al. 1998; Pope 1999;
Qiao et al. 2001; Slotkin 1999, 2004; Slotkin
et al. 2006; Whyatt et al. 2002).
In a recent study (Slotkin et al. 2006), we
compared the dose–effect relationships for
systemic toxicity and developmental neuro-
toxicity for chlorpyrifos, diazinon, and
parathion. Although parathion exhibited the
highest systemic toxicity, it was actually less
neurotoxic toward neurite formation and
development of cholinergic projections,
whereas diazinon and chlorpyrifos were less
systemically toxic and more neurotoxic. In
the present study we extended this approach
to the evaluation of serotonergic (5HT) sys-
tems in the neonatal rat brain. Studies with
chlorpyrifos show that 5HT systems are
among the most sensitive to developmental
disruption, with adverse effects detectable
even when exposures lie below the threshold
for inhibition of cholinesterase (Aldridge
et al. 2003, 2004, 2005a, 2005b, 2005c;
Qiao et al. 2002; Raines et al. 2001).
Targeting of 5HT function is critical for three
distinct reasons. First, 5HT is a morphogen
in the developing mammalian central nervous
system; perturbations of this system lead to
errors in the architectural assembly of the
brain (Hamon et al. 1989; Whitaker-Azmitia
1991, 2001). Second, disruption or enhance-
ment of 5HT synaptic communication in
early development permanently “programs”
future 5HT function, so even greater neuro-
behavioral anomalies emerge later (Aldridge
et al. 2004, 2005a, 2005b; Kusserow et al.
2004). Third, unlike the adverse effects on
cholinergic systems, which typically involve
cognitive deﬁcits, alterations in 5HT function
elicit changes in affective states, appetite, and
sleep patterns (Aldridge et al. 2005a;
Nemeroff 1998; Nutt 2002; Risch and
Nemeroff 1991), thus expanding the scope of
behavioral end points that need to be consid-
ered after early organophosphate exposure
(Aldridge et al. 2005a). In the present study,
we evaluated the immediate effects of neo-
natal treatment with doses of diazinon and
parathion below the maximum tolerated dose
(Slotkin et al. 2006) and spanning the thresh-
old for barely detectable cholinesterase inhibi-
tion. Measurements were conducted for three
5HT synaptic proteins known to be affected
by developmental exposure to chlorpyrifos
(Aldridge et al. 2003, 2004; Raines et al.
2001; Slotkin and Seidler 2005): 5HT1A and
5HT2 receptors and the presynaptic 5HT
transporter. The two receptors converge on
common end points in 5HT cell signaling
(Barnes and Sharp 1999; Morin et al. 1992;
Rovescalli et al. 1993) and are key players in
5HT-related mental disorders (Arango et al.
2001; Fujita et al. 2000; Yatham et al. 1999,
2000); the 5HT transporter regulates the
synaptic concentration of 5HT and is the
major target for antidepressant drugs (Maes
and Meltzer 1995; Nemeroff 1998; Nutt
2002). Evaluations were conducted in the
forebrain, which contains a high concentra-
tion of 5HT projections, and in the brain-
stem, which contains the corresponding cell
bodies.
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BACKGROUND: In the developing brain, serotonin (5HT) systems are among the most sensitive to
disruption by organophosphates. 
OBJECTIVES: We exposed neonatal rats to daily doses of diazinon or parathion on postnatal days
(PND)1–4 and evaluated 5HT receptors and the 5HT transporter in brainstem and forebrain on
PND5, focusing on doses of each agent below the maximum tolerated dose and spanning the
threshold for cholinesterase inhibition: 0.5, 1, or 2 mg/kg for diazinon, and 0.02, 0.05, and
0.1 mg/kg for parathion. 
RESULTS: Diazinon evoked up-regulation of 5HT1A and 5HT2 receptor expression even at doses
devoid of effects on cholinesterase activity, a pattern similar to that seen earlier for another
organophosphate, chlorpyrifos. In contrast, parathion decreased 5HT1A receptors, again at doses
below those required for effects on cholinesterase. The two agents also differed in their effects on
the 5HT transporter. Diazinon evoked a decrease in the brainstem and an increase in the forebrain,
again similar to that seen for chlorpyrifos; this pattern is typical of damage of nerve terminals and
reactive sprouting. Parathion had smaller, nonsigniﬁcant effects. 
CONCLUSIONS: Our results buttress the idea that, in the developing brain, the various organophos-
phates target speciﬁc neurotransmitter systems differently from each other and without the require-
ment for cholinesterase inhibition, their supposed common mechanism of action.
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insecticides, parathion, serotonin receptors, serotonin transporter. Environ Health Perspect
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Animal treatments. All experiments were car-
ried out humanely and with regard for allevia-
tion of suffering, with protocols approved by
the Institutional Animal Care and Use
Committee and in accordance with all federal
and state guidelines. Timed-pregnant Sprague-
Dawley rats (Charles River, Raleigh, NC) were
housed in breeding cages, with a 12-hr
light/dark cycle and free access to food and
water. On the day of birth, all pups were ran-
domized and redistributed to the dams with a
litter size of 9–10 to maintain a standard nutri-
tional status. Because of their poor water solu-
bility, diazinon and parathion (both from
Chem Service, West Chester, PA) were dis-
solved in dimethylsulfoxide (DMSO) to pro-
vide consistent absorption (Whitney et al.
1995) and were injected subcutaneously in a
volume of 1 mL/kg once daily on postnatal
days (PND)1–4; control animals received
equivalent injections of DMSO vehicle, which
does not itself produce developmental neuro-
toxicity (Song et al. 1998; Whitney et al. 1995).
Doses were chosen to lie below the threshold
for signs of systemic toxicity as evidenced by
impaired viability or reduced weight gain
(Slotkin et al. 2006): 0.5, 1, and 2 mg/kg for
diazinon, and 0.02, 0.05, and 0.1 mg/kg of
parathion. The highest dose of each agent rep-
resents the maximum tolerated dose (Slotkin
et al. 2006). On PND5, one male and one
female pup were selected from each of at least
six litters in each treatment group and were
used for neurochemical evaluations. Animals
were decapitated, the cerebellum was removed,
and the brainstem and forebrain were separated
by a cut made rostral to the thalamus. Tissues
were weighed and ﬂash frozen in liquid nitro-
gen and maintained at –45°C until analyzed.
For a supplemental study determining the
degree of cholinesterase inhibition immediately
after treatment, additional animals were used to
obtain samples 2 hr after the last injection of
2 mg/kg of diazinon or vehicle on PND4.
Assays. Assays were conducted on each indi-
vidual tissue, so that each determination repre-
sented a value from the corresponding brain
region of one animal. Each tissue was thawed
and homogenized (Polytron; Brinkmann
Instruments, Westbury, NY) in ice-cold
50 mM Tris (pH 7.4), and aliquots of the
homogenate were withdrawn for measurement
of total protein (Smith et al. 1985) and
cholinesterase activity (Ellman et al. 1961). For
the latter, the homogenate was diluted in 0.5%
Triton X-100, 0.1 M Na2HPO4/KH2PO4
(pH 8), and left on ice for 15 min to allow the
Triton X-100 to solubilize membrane-associ-
ated cholinesterase. Homogenates were sedi-
mented at 40,000 × g for 15 min, and aliquots
of the supernatant solution were added to ﬁnal
concentrations of 0.5 mM acetylthiocholine
iodide and 0.33 mM 5,5´-dithiobis(2-nitro-
benzoic acid) in the same buffer without
Triton (all reagents from Sigma Chemical Co.,
St. Louis, MO). Assays were incubated at room
temperature for 4, 8, 12, 16, and 20 min, and
the enzyme activity was assessed from the lin-
ear portion of the time course, reading the
absorbance at 415 nm. The assay was standard-
ized using mercaptoethanol standards and cal-
culated relative to total protein.
The remaining homogenate was sedi-
mented at 40,000 × g for 15 min; the resultant
pellet was then washed by resuspension
(Polytron) in homogenization buffer followed
by resedimentation, and was then dispersed
with a homogenizer (smooth glass ﬁtted with
Teﬂon pestle) in 50 mM Tris buffer (pH 7.4).
An aliquot was withdrawn for the determina-
tion of membrane protein (Smith et al. 1985).
Two radioligands were used to determine
5HT receptor binding (Xu et al. 2002): 1 nM
[3H]8-hydroxy-2-(di-n-propylamino)tetralin
(speciﬁc activity, 135 Ci/mmol; PerkinElmer
Life Sciences, Boston, MA) for 5HT1A recep-
tors (Park et al. 1999; Stockmeier et al. 1998),
and 0.4 nM [3H]ketanserin (speciﬁc activity,
63 Ci/mmol; PerkinElmer) for 5HT2 recep-
tors (Leysen et al. 1982; Park et al. 1999). For
5HT1A receptors, incubations lasted 30 min at
25°C in a buffer consisting of 50 mM Tris
(pH 8), 2 mM MgCl2, and 2 mM sodium
ascorbate; 100 µM 5HT (Sigma) was used to
displace speciﬁc binding. For 5HT2 receptors,
incubations lasted 15 min at 37°C in 50 mM
Tris (pH 7.4), and specific binding was dis-
placed with 10 µM methylsergide (Sandoz
Pharmaceuticals, E. Hanover, NJ). Incubations
were stopped by the addition of a large excess
of ice-cold buffer, and the labeled membranes
were trapped by rapid vacuum ﬁltration onto
glass ﬁber ﬁlters that were presoaked in 0.15%
polyethyleneimine (Sigma). The filters were
then washed repeatedly and radiolabel was
determined. For binding to the presynaptic
5HT transporter (Moret and Briley 1991;
Slotkin et al. 1997, 1999, 2000; Xu et al.
2001), the membrane suspension was incu-
bated with 85 pM [3H]paroxetine (specific
activity 19.4 Ci/mmol; PerkinElmer) with or
without addition of 100 µM 5HT to displace
specific binding, and incubations lasted
120 min at 20°C. Binding was calculated rela-
tive to membrane protein.
Data analysis. Data were compiled as
means ± SEs. Because we evaluated multiple
neurochemical variables that were all related to
5HT synapses, the initial comparison was con-
ducted by a global analysis of variance
(ANOVA; data log-transformed because of
heterogeneous variance between regions and
measures) incorporating all the variables and
measurements in order to avoid an increased
probability of type 1 errors that might other-
wise result from multiple tests of the same data
set: treatment, sex, region, and the three meas-
ures (5HT1A receptors, 5HT2 receptors, 5HT
transporter; repeated measure). Similarly, for
cholinesterase activity, the initial ANOVA
examined treatment, sex, and region. Where we
identified interactions of treatment with the
other variables, data were then subdivided for
lower-order ANOVAs, followed by Fisher’s
protected least signiﬁcant difference test to eval-
uate individual treatments that differed from
the corresponding control. However, where
interactions are not signiﬁcant, we report only
the main treatment effects. Significance was
assumed at the level of p < 0.05. For conve-
nience, some of the results are presented as the
percent change from control values, but statisti-
cal comparisons were conducted only on the
original data. For reference, the corresponding
control values are shown in Table 1.
Results
The doses we chose for daily treatment of
neonatal rats with diazinon or parathion on
PND1–4 spanned the threshold for signifi-
cant inhibition of cholinesterase in the brain-
stem and forebrain (Figure 1). Twenty-four
Organophosphate developmental neurotoxicity
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Table 1. Control values.
Brainstem Forebrain
Male Female Male Female
5HT1A receptors (fmol/mg membrane protein) 62 ± 1 64 ± 2 49 ± 2 53 ± 1
5HT2 receptors (fmol/mg membrane protein) 33 ± 1 32 ± 1 42 ± 1 45 ± 1
5HT transporter (fmol/mg membrane protein) 390 ± 8 392 ± 6 174 ± 5 184 ± 4
Cholinesterase (nmol/min/mg total protein) 79 ± 3 79 ± 2 31 ± 1 32 ± 1
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Figure 1. Cholinesterase activity on PND5, 24 hr after
the last dose of diazinon or parathion. Abbreviations:
bs, brainstem; fb, forebrain. Data are presented as
the percentage change from control values
(Table 1). ANOVA across all contributing variables
indicates a main treatment effect (p < 0.0001) and an
interaction of treatment × sex (p < 0.003); treatment
effects were significant in both males (p < 0.0009)
and females (p < 0.0001). 
*Signiﬁcantly different from control (main effect without a
treatment × sex interaction). **Signiﬁcantly different from
control males. #Signiﬁcantly different from control females.hours after the final injection, there was no
signiﬁcant inhibition in either the brainstem
or forebrain at the lowest dose of diazinon
(0.5 mg/kg). At 1 mg/kg, there was a barely
detectable (< 10%) inhibition that achieved
statistical significance in females but not in
males, and at 2 mg/kg both sexes showed
detectable inhibition. At the highest dose,
cholinesterase was still inhibited only about
10% in males and 20% in females. With
parathion treatment, neither 0.02 nor
0.05 mg/kg evoked signiﬁcant cholinesterase
inhibition. Raising the dose to 0.1 mg/kg
produced statistically significant inhibition
that was still only 5–15%.
Cholinesterase activity recovers much
more quickly in developing animals than in
adults because of the rapid, growth-associated
synthesis of new cholinesterase molecules
(Chakraborti et al. 1993; Lassiter et al. 1998).
Accordingly, we performed an additional
experiment in which cholinesterase was meas-
ured 2 hr after the ﬁnal injection of the high-
est dose of diazinon (Figure 2), a time point
corresponding to the peak of inhibition (Dam
et al. 2000). Under these conditions, there
was somewhat more inhibition (25–30%)
than that seen at the 24-hr time point, but
the amount still was far less than the 70%
inhibition threshold for signs of cholinergic
hyperstimulation and systemic toxicity (Clegg
and van Gemert 1999).
Both diazinon and parathion elicited sig-
nificant effects on 5HT receptors and the
5HT transporter. Across all three measures
and all contributing variables, global ANOVA
indicated a significant main treatment effect
(p < 0.0001) that reflected alterations for
0.5 or 1 mg/kg of diazinon (p < 0.0004 and
p < 0.0006, respectively), and for 0.1 mg/kg of
parathion (p < 0.02). However, the treatment
effect also depended both on sex and region
and on the specific measurement being
made (treatment × sex × region × measure,
p < 0.006). Accordingly, we subdivided the
results for the three different proteins (5HT1A
receptor, 5HT2 receptor, 5HT transporter)
and reexamined treatment effects across
region and sex for each one separately.
Neonatal treatment with diazinon or
parathion produced significant changes in
5HT1A receptor binding, reflecting a main
treatment effect and a treatment × sex inter-
action, with signiﬁcant effects for both males
and females (Figure 3A). For diazinon, the
two lower doses, 0.5 and 1 mg/kg, showed sig-
niﬁcant overall elevations without distinction
between brainstem and forebrain and without
preferential effects for males compared with
females. Raising the dose to 2 mg/kg dimin-
ished the response so that it became non-
signiﬁcant. We observed a different pattern for
parathion, which caused a signiﬁcant decrease
instead of increasing 5HT1A receptor binding.
Although there was no effect at the lowest
dose of parathion, the intermediate dose
elicited a signiﬁcant reduction in females and
the highest dose evoked a reduction in both
sexes. The effects on 5HT2 receptors were also
statistically signiﬁcant but generally of smaller
magnitude than those seen for the 5HT1A sub-
type (Figure 3B). In this case, there was only a
main treatment effect, so no lower-order tests
were run for separate regions or sexes. Again,
the two lower doses of diazinon elicited a sta-
tistically signiﬁcant increase in 5HT2 receptor
binding, whereas the highest dose did not.
Parathion did not have significant effects at
any dose.
For the 5HT transporter, there was a sig-
nificant treatment × region interaction
(Figure 4A), necessitating separate examina-
tion of the effects in the brainstem (Figure 4B)
and forebrain (Figure 4C). Because there was
no treatment × sex interaction, we show the
results for males and females combined. In the
brainstem, diazinon reduced transporter
expression but only at the highest dose;
parathion had no effect. In the forebrain,
diazinon increased the values significantly,
whereas parathion was less effective (not statis-
tically signiﬁcant).
Discussion
In our earlier work with chlorpyrifos, we found
that exposure in the early postnatal period
elicited an immediate increase in 5HT receptor
expression (Aldridge et al. 2003). Because these
effects occurred during the critical period in
which 5HT synaptic development and func-
tion are programmed (Kusserow et al. 2004),
much larger alterations appeared in adoles-
cence and adulthood, accompanied by defec-
tive 5HT synaptic transmission and behavioral
deﬁcits (Aldridge et al. 2004, 2005a, 2005b).
In the present study, diazinon elicited a similar
up-regulation of 5HT receptors, demonstrat-
ing that the effects are not unique to chlorpyri-
fos. Nevertheless, this is not a property shared
by all organophosphates; parathion failed to
increase 5HT receptor expression, and instead
evoked a decrease with exposures approaching
the maximum tolerated dose (Slotkin et al.
2006). This dichotomy argues strongly against
a speciﬁc role of cholinesterase inhibition as a
common mechanism underlying the develop-
mental neurotoxicity of organophosphates.
Indeed, just as found previously for chlorpyri-
fos (Aldridge et al. 2003; Qiao et al. 2002), the
effects of diazinon on 5HT systems were
apparent at exposures below the threshold for
cholinesterase inhibition. In fact, raising the
dose above that threshold actually diminished
the 5HT receptor up-regulation, suggesting
that there is a nonmonotonic dose–effect rela-
tionship, with promotional actions at low
doses offset by inhibitory ones as the exposure
is raised above the threshold for cholinesterase-
related systemic toxicity. Again, similar ﬁnd-
ings of a biphasic response have been reported
for neurodevelopmental effects of chlorpyrifos
(Levin et al. 2002; Qiao et al. 2002). The
Slotkin et al.
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Figure 2. Cholinesterase activity on PND4, 2 hr
after the last dose of 2 mg/kg diazinon. ANOVA
across all contributing variables indicates a signiﬁ-
cant main treatment effect (p < 0.0001); results for
males and females were combined because of the
absence of a treatment × sex interaction. 
*Signiﬁcantly different from control.
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Figure 3. Effects of PND1–4 diazinon or parathion treatment on 5HT1A receptors (A) and 5HT2 receptors (B).
Abbreviations: bs, brainstem; fb, forebrain. Data are presented as the percentage change from control values
(Table 1). For 5HT1A receptors, ANOVA across all contributing variables indicates a main treatment effect
(p < 0.0001) and a treatment × sex interaction (p < 0.02), with signiﬁcant treatment effects for both males and
females (p < 0.0001 for each). For 5HT2 receptors, there was only a main treatment effect (p < 0.03), so lower
order tests for each sex were not conducted. 
*Signiﬁcantly different from control (main effect without a treatment ×sex interaction). #Signiﬁcantly different from control females.effects of diazinon on 5HT receptors in the
present study thus resemble those of chlorpyri-
fos in direction and magnitude (Aldridge et al.
2003). Future studies should address whether,
like chlorpyrifos, these events presage much
larger changes that emerge in adolescence and
adulthood (Aldridge et al. 2004, 2005a,
2005b). In contrast, based on the opposite
effect of parathion on 5HT receptors observed
in the present study, we would predict an
entirely different long-term outcome for expo-
sure to that organophosphate.
In contrast to its promotional effects on
5HT receptors, diazinon had differential effects
on expression of the 5HT transporter in the
two brain regions. In the brainstem, diazinon
reduced transporter binding values, but only
when the dose was raised above the threshold
for cholinesterase inhibition; in contrast, values
were elevated in the forebrain even at low
doses. Again, these are generally similar to the
results from our earlier work with chlorpyrifos
(Raines et al. 2001), although the effects of
diazinon are more robust. With cholinergic
agonists such as nicotine, damage to neuronal
projections in the forebrain results in reactive
sprouting at the cell body (Xu et al. 2001); if
diazinon were similar, we would have seen
reductions in 5HT transporter expression in
the forebrain and increases in the brainstem,
the opposite of what we actually obtained. On
the other hand, neurotoxicants that directly
target developing monoamine terminals tend
to produce sprouting further along the axon,
thus producing the corresponding increment
in the forebrain, which contains the terminal
zone (Blue and Molliver 1987), just as seen
here. Again, this argues strongly for effects of
diazinon (and potentially of chlorpyrifos as
well) on developing 5HT projections that are
independent of effects on cholinesterase or
cholinergic systems. Notably, parathion was far
less effective (no signiﬁcant changes) for such
actions in either brain region, reinforcing the
fact that the various organophosphates can
elicit different outcomes. Chlorpyrifos has
already been shown to have differential effects
on dendritic versus axonal outgrowth (Howard
et al. 2005); therefore, it is likely that diazinon
has similarly disparate effects on different types
of neuritic projections.
The case of parathion is particularly
intriguing, especially given its much greater
systemic toxicity, which has a maximum tol-
erated dose over an order of magnitude lower
than that of chlorpyrifos or diazinon in
neonatal rats (Liu et al. 1999; Slotkin et al.
2006). We previously found that parathion,
at its maximum tolerated dose, did not com-
promise the development of neuritic projec-
tions or emergence of the cholinergic
phenotype, whereas chlorpyrifos did (Jameson
et al. 2006; Slotkin et al. 2006). In the pre-
sent study, parathion, even at a dose below
the threshold for cholinesterase inhibition,
had a deleterious effect on the development of
5HT1A receptors, a unique effect not shared
by diazinon or chlorpyrifos (Aldridge et al.
2003). Accordingly, parathion “spares” devel-
oping neurites and cholinergic projections
because its greater systemic toxicity limits the
dose that can be given, rather than because it
is inherently less neurotoxic (Slotkin et al.
2006). However, in the case of 5HT systems,
it appears to have additional, direct effects
that are independent of cholinesterase inhibi-
tion and that can be evoked below the maxi-
mum tolerated dose. Again, it will be useful
to pursue the long-term neurochemical and
behavioral consequences of these actions.
Conclusion
Our results bolster the idea that, in the devel-
oping brain, the various organophosphates
target specific neurotransmitter systems 
differently and without the requirement for
cholinesterase inhibition, their supposed com-
mon mechanism of action (Mileson et al.
1998). In fact, the 5HT system is especially
vulnerable to disruption by diazinon, chlor-
pyrifos, and parathion, with parathion showing
a distinctly different spectrum of actions from
the other two agents. The fact that alterations
in neurodevelopment occur with organo-
phosphate exposures below the threshold for
cholinesterase inhibition reinforces the inade-
quacy of this biomarker for assessing exposure
or outcome related to developmental neuro-
toxicity. Finally, the differential effects of the
various organophosphates raise the intriguing
possibility that safer compounds could be engi-
neered that avoid the critical mechanisms
evoking developmental neurotoxicity.
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